IMMUNOVANT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
IMMUNOVANT, INC. (IMVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 6.87 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 6.87K shares, a 0.41% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 48.91K shares, a 939.57% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 17.08K shares.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 25.73K shares.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2026 was 98.61K shares, a 613.06% increase from fiscal 2025.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 13.83K shares, a 122.22% increase from fiscal 2024.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 6.22K shares, a 80.19% decline from fiscal 2023.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 31.41K shares, a 79.92% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.87K shares 10-Q · filed 2026-08-06 | 55.78K shares derived: sum of 2 quarters · filed 2026-08-06 | 72.86K shares derived: sum of 3 quarters · filed 2026-08-06 | 98.58K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 48.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | 65.99K shares derived: sum of 2 quarters · filed 2026-05-20 | 91.72K shares derived: sum of 3 quarters · filed 2026-05-20 | 98.61K shares 10-K · filed 2026-05-20 |
| 2025-12-31 | 17.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | 42.80K shares derived: sum of 2 quarters · filed 2026-02-06 | 49.70K shares 10-Q · filed 2026-02-06 | 54.40K shares derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-09-30 | 25.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | 32.62K shares 10-Q · filed 2025-11-10 | 37.32K shares derived: sum of 3 quarters · filed 2025-11-10 | |
| 2025-06-30 | 6.89K shares 10-Q · filed 2025-08-11 | 11.60K shares derived: sum of 2 quarters · filed 2025-08-11 | ||
| 2025-03-31 | 4.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | 13.83K shares 10-K · filed 2025-05-29 | ||
| 2024-12-31 | 9.12K shares 10-Q · filed 2025-02-06 | |||
| 2024-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-29 | 2.60K shares derived: sum of 2 quarters · filed 2024-05-29 | 2.60K shares derived: sum of 3 quarters · filed 2024-05-29 | 6.22K shares 10-K · filed 2024-05-29 |
| 2023-12-31 | 2.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | 2.60K shares derived: sum of 2 quarters · filed 2024-02-12 | 6.22K shares 10-Q · filed 2024-02-12 | 6.22K shares derived: sum of 4 quarters · filed 2024-02-12 |
| 2023-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-09 | 3.63K shares 10-Q · filed 2023-11-09 | 3.63K shares derived: sum of 3 quarters · filed 2023-11-09 | 9.92K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 3.63K shares 10-Q · filed 2023-08-10 | 3.63K shares derived: sum of 2 quarters · filed 2023-08-10 | 9.92K shares derived: sum of 3 quarters · filed 2023-08-10 | 25.46K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | 6.29K shares derived: sum of 2 quarters · filed 2023-05-22 | 21.83K shares derived: sum of 3 quarters · filed 2023-05-22 | 31.41K shares 10-K · filed 2023-05-22 |
| 2022-12-31 | 6.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-03 | 21.83K shares derived: sum of 2 quarters · filed 2023-02-03 | 31.41K shares 10-Q · filed 2023-02-03 | 42.66K shares derived: sum of 4 quarters · filed 2023-02-03 |
| 2022-09-30 | 15.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-04 | 25.11K shares 10-Q · filed 2022-11-04 | 36.37K shares derived: sum of 3 quarters · filed 2022-11-04 | 140.90K shares derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-06-30 | 9.58K shares 10-Q · filed 2022-08-05 | 20.83K shares derived: sum of 2 quarters · filed 2022-08-05 | 125.36K shares derived: sum of 3 quarters · filed 2022-08-05 | |
| 2022-03-31 | 11.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | 115.78K shares derived: sum of 2 quarters · filed 2022-06-08 | 156.41K shares 10-K · filed 2022-06-08 | |
| 2021-12-31 | 104.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-04 | 145.16K shares 10-Q · filed 2022-02-04 | ||
| 2021-09-30 | 40.63K shares 10-Q · filed 2021-11-05 | |||
| 2021-03-31 | -225.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | -225.40K shares derived: sum of 2 quarters · filed 2021-06-01 | -225.40K shares derived: sum of 3 quarters · filed 2021-06-01 | 833.00 shares 10-K · filed 2021-06-01 |
| 2020-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-16 | 0.00 shares derived: sum of 2 quarters · filed 2021-02-16 | 226.23K shares 10-Q · filed 2021-02-16 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | 226.23K shares 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 226.23K shares 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | 382.27K shares 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |